KORU Medical Systems Recruits Edward Wholihan to Its Board

KORU Medical Systems Inc. has appointed Edward Wholihan to its Board of Directors.
 
“I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shareholder value in high-growth life science and healthcare businesses,” KORU Medical President/CEO Linda Tharby said. “As we continue to build our leadership position in the subcutaneous infusion market with our FREEDOM Infusion System, Ed’s insights will meaningfully contribute to our future growth and success.”
 
Wholihan joins KORU Medical’s board with more than 25 years of experience as chief financial officer (CFO) driving growth and shareholder value for public, private equity-sponsored, and venture capital-funded life sciences and healthcare businesses. Most recently, he has leveraged his strategic management, financial, and operational expertise consulting for various companies. Prior to that, he served as CFO for Rarebreed Veterinary Partners Inc, a community of veterinary hospitals; CFO of Allena Pharmaceuticals Inc., a development stage biopharmaceutical company; and CFO of Medical Specialties Distributors, a solution provider to the specialty pharmacy, home infusion, and oncology practice markets that was acquired by McKesson Corp in 2018. Wholihan also held two other CFO roles within the life science sector earlier in his career and, prior to that, spent seven years as a management strategy consultant for McKinsey & Company.

Wholihan earned his MBA from Stanford University’s Graduate School of Business and a bachelor of arts degree in economics from Yale University.
 
“I am impressed with KORU Medical’s progress, innovation, and commitment toward growth, and I am excited to take part in helping the company improve the quality of life for patients around the world,” Wholihan stated. “I look forward to supporting Linda and the KORU Medical team as they continue to drive the company’s growth strategy and the provision of subcutaneous infusion therapies and their benefits to patients.”
 
KORU Medical Systems develops, manufactures, and commercializes easy-to-use subcutaneous drug delivery systems that improve quality of life for patients around the world. The FREEDOM Infusion System currently includes the FREEDOM60 and FreedomEdge Syringe Infusion Drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. These devices are used for infusions administered in the home and alternate care settings.